US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
WDC
$415.29
▲+0.00%
SDEV
$7.48
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
WDC
$415.29
▲+0.00%
SDEV
$7.48
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Oric Pharmaceuticals, Inc. - Common Stock
(NQ:
ORIC
)
12.21
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Oric Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 03, 2025
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 06, 2025
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Oric Pharma Stock Hits 3-Month High On Promising Results In Prostate Cancer Trial
↗
May 29, 2025
The company also announced a $125 million private placement to fund its upcoming Phase 3 trial for ORIC-944 in metastatic prostate cancer.
Via
Stocktwits
Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results
↗
May 29, 2025
Via
Benzinga
Keep an eye on the top gainers and losers in Thursday's session.
↗
May 29, 2025
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via
Chartmill
ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital
↗
May 29, 2025
ORIC's Phase 1b trial of ORIC-944 in mCRPC shows PSA responses and strong tolerability, with Phase 3 trials and financing plans underway.
Via
Benzinga
The market is filled with gapping stocks in Thursday's session.
↗
May 29, 2025
Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via
Chartmill
Veeva Systems, e.l.f. Beauty, C3.ai, BRP And Other Big Stocks Moving Higher On Thursday
↗
May 29, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
May 29, 2025
Via
Benzinga
Why Nvidia Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket
↗
May 29, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
May 28, 2025
Via
Benzinga
Get insights into the top gainers and losers of Wednesday's after-hours session.
↗
May 28, 2025
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via
Chartmill
ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing
May 28, 2025
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC
May 28, 2025
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
May 27, 2025
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC
May 27, 2025
Conference Call and Webcast on Wednesday, May 28, 2025, at 4:30 p.m. ET
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates
May 05, 2025
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 02, 2025
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting
April 28, 2025
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 04, 2025
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
March 31, 2025
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
March 25, 2025
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 07, 2025
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones
February 25, 2025
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
February 18, 2025
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tuesday's session: gap up and gap down stocks
↗
February 11, 2025
Let's have a look at the gap up and gap down stocks in today's session.
Via
Chartmill
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
January 27, 2025
From
ORIC Pharmaceuticals
Via
GlobeNewswire
H&E Equipment Services, ACM Research, Robinhood And Other Big Stocks Moving Higher On Tuesday
↗
January 14, 2025
Via
Benzinga
ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones
January 13, 2025
From
ORIC Pharmaceuticals
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
